|Other names||H-D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH2; D-Arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide|
|Chemical and physical data|
|Molar mass||639.802 g·mol−1|
Elamipretide (also known as SS-31, , MTP-131 and Bendavia) is a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that appears to reduce the production of toxic reactive oxygen species and stabilize cardiolipin.
Stealth Peptides, a privately held company, was founded in 2006 to develop intellectual property licensed from several universities including elamipretide; it subsequently changed its name to Stealth BioTherapeutics.
As of November 2017 Stealth had obtained an orphan designation in the US for use in mitochondrial myopathy and had started a Phase III trial in that indication. As of January 2020, trial expectations were not met.
- "Recommended INN List 75" (PDF). WHO Drug Information. 30 (1): 111. 2016.
- "Elamipretide". AdisInsight. Retrieved 29 November 2017.
- Kloner RA, Shi J, Dai W (February 2015). "New therapies for reducing post-myocardial left ventricular remodeling". Annals of Translational Medicine. 3 (2): 20. doi:10.3978/j.issn.2305-5839.2015.01.13. PMC 4322169. PMID 25738140.
- Valigra L (April 9, 2012). "Stealth Peptides sees positive results from Bendavia". Boston Business Journal.
- Dolgin E (11 February 2016). "New drugs offer hope for mitochondrial disease". STAT.
- PhD, Alberto Molano (2020-01-10). "Elamipretide Failed to Meet Promise of Earlier Trial Results for..." Mitochondrial Disease News. Retrieved 2020-02-24.